

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioner,

v.

ASCLETIS PHARMA CHINA CO. LTD.,
Patent Owner.

Case No. PGR2025-00057
Patent No. 12,234,236
Title: GLP-1R agonist and therapeutic method thereof

PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description of Document
2001	Declaration of Geoffrey D. Biegler (“Biegler”)
2002	Excerpts of File History of U.S. Patent No. 12,234,236
2003	Excerpts of File History of U.S. Patent Application No. 18/885,065
2004	International Publication No. WO 2025/131043A1
2005	Certified English Translation of International Publication No. WO 2025/131043A1
2006	U.S. Patent No. 12,291,530
2007	Guang Huang et al., <i>Applications of Oxetanes in Drug Discovery and Medicinal Chemistry</i> , European Journal of Medicinal Chemistry (2023), 261
2008	Juan J. Rojas and James A. Bull, <i>Oxetanes in Drug Discovery Campaigns</i> , Journal of Medicinal Chemistry (2023), 66 , 12697-12709
2009	Jonas Boström et al., <i>Oxadiazoles in Medicinal Chemistry</i> , Journal of Medicinal Chemistry (2011), 55, 1817-1830
2010	Yijing Li et al., <i>Thiadiazole—a Promising Structure in Medicinal Chemistry</i> , ChemMedChem (2013), 27-41
2011	Bethany R. Shire and Edward A. Anderson, <i>Conquering the Synthesis and Functionalization of Bicyclo[1.1.1]pentanes</i> , An Open Access Journal of the American Chemical Society (2023), 3, 1539-1553
2012	Edon Vitaku, David T. Smith, and Jon T. Njardarson, <i>Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</i> , Journal of Medicinal Chemistry (2014), 57, 10257-10274
2013	Marcelo D. Polêto et al., <i>Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities</i> , Frontiers in Pharmacology (2018), 9, 1-20
2014	Aimee K. Clarke and William P. Unsworth, <i>A happy medium: the synthesis of medicinally important medium-sized rings via ring expansion</i> , The Royal Society of Chemistry (2020), 11, 2876-2881

Exhibit No.	Description of Document
2015	Alexander S. Harmata, Madison J. Sowden, and Corey R. J. Stephenson, <i>Bridged bicyclic building block upgrading: Photochemical synthesis of bicyclo[3.1.1]heptan-1-amines</i> , Willard Henry Dow Laboratory, Dept. of Chemistry, Univ. of Michigan
2016	Jang Won Son and Soo Lim, <i>Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management</i> , Endocrinology and Metabolism (2024), 39, 206-221
2017	Sean Wharton, M.D. et al., Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, The New England Journal of Medicine (2023), 389, 877-888 (https://www.nejm.org/doi/10.1056/NEJMoa2302392)
2018	<i>A Study of Orforglipron (LY3502970) in Adult Participants with Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)</i> , Lilly Trials, https://trials.lilly.com/en-US/trial/403875 (last visited Oct. 6, 2025)
2019	International Publication No. WO 2024/169952 A1
2020	International Publication No. WO 2023/016546 A1
2021	International Publication No. WO 2024/153070 A1
2022	<i>Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting</i> , Ascletis, https://www.ascletis.com/news_detail/192/id/1243.html (last visited Oct. 6, 2025)
2023	Jinzi Jason Wu and Vanessa Wang, <i>Poster number: 750-P, ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity -A First-in-Human Single Ascending Dose Study</i> , (June 20, 2025), https://www.ascletis.com/data/upload/ueditor/20250618/ASC30_poster_@_ADA_2025.pdf
2024	<i>Compound Summary for CID 8028, Tetrahydrofuran</i> , National Center for Biotechnology Information, PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Tetrahydrofur an

Exhibit No.	Description of Document
2025	<i>Compound Summary for CID 9253, Cyclopentane</i> , National Center for Biotechnology Information, PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Cyclopentane (last visited Oct. 6, 2025)
2026	Arun K Ghosh and David D Anderson, <i>Tetrahydrofuran, Tetrahydropyran, Triazoles and Related Heterocyclic Derivatives as Hiv Protease Inhibitors</i> , <i>Future Med Chem.</i> (2011), 3, 1181-1197
2027	Seung-Hwa Kwak et al., <i>Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition</i> , <i>Journal of Medicinal Chemistry</i> (2020), 63, 6821-6833
2028	Pedro de Sena Murteira Pinheiro, Lucas Silva Franco and Carlos Alberto Manssour Fraga, <i>The Magic Methyl and Its Tricks in Drug Discovery and Development</i> , <i>MDPI</i> (2023), 16, 1157
2029	Declaration of Isha Agarwal (“Agarwal”)
2030	Bio of Tae Yeon (Zoe) Kim (“Kim Bio”)
2031	Declaration of Tae Yeon (Zoe) Kim (“Kim”)
2032	Fredrik Bergström and Bo Lindmark, <i>Accelerated drug discovery by rapid candidate drug identification</i> , <i>Drug Discovery Today</i> , Vol. 24, No. 6 (June 2019)
2033	Deposition transcript of Michael Pirrung taken on February 26, 2026
2034	Camile Georges Wermuth, David Aldous, Pierre Raboisson and Didier Rognan, <i>The Practice of Medicinal Chemistry</i> , 4th ed. (2015)
2035	B. Sun et al., RCSB PDB of PDB ID 6XOX, <i>cryo-EM of human GLP-1R bound to non-peptide agonist LY3502970</i> , RCSB PROTEIN DATA BANK, https://www.rcsb.org/3d-view/6XOX
2036	Michael Reddy, <i>Standard amino acids</i> , (https://www.britannica.com/science/amino-acid/Standard-amino-acids) (last visited Mar. 2, 2026)
2037	Francis A. Carey and Richard J. Sundberg, <i>Advanced Organic Chemistry, Part A: Structure and Mechanisms</i> , 5th Ed. (2007)

Exhibit No.	Description of Document
2038	Neil Vargesson, <i>Thalidomide-Induced Teratogenesis: History and Mechanisms</i> , Birth Defects Research (Part C) 105:140–156 (2015)
2039	James Burnett et al., <i>A threonine turnstile defines a dynamic amphiphilic binding motif in the AAA ATPase p97 allosteric binding site</i> , Org. Biomol. Chem., Vol. 15, 4096 (2017)
2040	Celeste Alvarez, et al., <i>Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97</i> , ACS Med. Chem. Lett., Vol. 6, 1225-1230 (2015)
2041	Angela Kerekes, et al., <i>Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation improve Oral Absorption and Exposure</i> , J. Med. Chem., Vol. 54, 201-210 (2011)
2042	Ascletis, <i>Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight</i> (Dec. 8, 2025)
2043	Tong & Whitesell, <i>In Situ Salt Screening</i> , Pharm. Dev. & Tech., 3(2):215, 217 (1998)
2044	Michael J. Bowker, <i>A Procedure for Salt Selection and Optimization</i> , Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Ch. 7
2045	Stephen M. Berge, Lyle D. Bighley and Donald C. Monkhouse, <i>Pharmaceutical Salts</i> , J. Pharm. Sci., 66:1-19 (1977)
2046	Faisal Malik and Zhijun Li, <i>Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: Alternative approaches for treatment of Type 2 diabetes</i> , British Pharm. Society, 511, 514 (2021)
2047	Edith Wing-Kar Chow and Elaine Chow, <i>Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity</i> , The Lancet (Dec. 20, 2025), https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02381-5/abstract?rss=yes

Exhibit No.	Description of Document
2048	<i>Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus</i> , Pfizer (June 26, 2023), https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development
2049	Neeta B. Amin et al., <i>Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study</i> , <i>Diabetes Obesity Metab.</i> 2025; 27:215–227 (2024)
2050	<i>Pfizer Provides Update on GLP-1 Receptor Agonist Danuglipron</i> , Pfizer (April 14, 2025), https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist
2051	James Waldron, <i>Pfizer’s Embattled Obesity Program Loses Another GLP-1 Over Poor Data and Strong Competition</i> , <i>Fierce Biotech</i> (Aug. 5, 2025), https://www.fiercebiotech.com/biotech/pfizers-embattled-obesity-program-loses-another-glp-1-drug
2052	Malcolm Huestis and Keith Fagnou, <i>Site-Selective Azaindole Arylation at the Azine and Azole Rings via N-Oxide Activation</i> , <i>Organic Lett.</i> , Vol. 11, No. 6 1357-1360 (2009)
2053	Matthew Ward and Niamh O’Boyle, <i>Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014-2023)</i> , <i>RSC Medicinal Chem.</i> 16, 4540-4570 (2025), https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00403a (last visited March 3, 2026)
2054	Edon Vitaku et al., <i>Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</i> , <i>J. Med. Chem.</i> , Vol. 57, Issue 24 (2014), https://pubs.acs.org/doi/10.1021/jm501100b (last visited March 3, 2026)

Exhibit No.	Description of Document
2055	Aimee Clarke and William Unsworth, <i>A happy medium: the synthesis of medicinally important medium-sized rings via ring expansion</i> , Chem. Sci., Vol. 11, 2846 (2020), https://pubs.rsc.org/en/content/articlehtml/2020/sc/d0sc00568a (last visited March 3, 2026)
2056	Marcelo Polêto, et al., <i>Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities</i> , Front. Pharmacol., 9:395 (2018), https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00395/full (last visited March 3, 2026)
2057	Juan Rojas and James Bull, <i>Oxetanes in Drug Discovery Campaigns</i> , J. Med. Chem., 66, 12697-12709 (2023), https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01101 (last visited March 3, 2026)
2058	Mohana Krishna Ramisetty et al., <i>Exploration of Oxetanes and Azetidines in Structure-Based Drug Design</i> , Synlett 37(01):123-134 (2026), https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2698-0616 (last visited March 3, 2026)
2059	Guang Huang, et al., <i>Applications of oxetanes in drug discovery and medicinal chemistry</i> , E.J. of Med. Chem., 261 (2023), https://www.sciencedirect.com/science/article/pii/S022352342300769 (last visited March 3, 2026)
2060	Volodymyr Semeno et al., <i>Bicyclo[m.n.k]alkane Building Blocks as Promising Benzene and Cycloalkane Isosteres: Multigram Synthesis, Physicochemical and Structural Characterization</i> , Nov. 14, 2023, https://chemrxiv.org/engage/chemrxiv/article-details/65416d4ec573f893f18864ed (last visited March 3, 2026)
2061	Alexander Harmata, et al., <i>Bridged Bicyclic Building Block Upgrading: Photochemical Synthesis of bicyclo[3.1.1]heptan-1-Amines</i> , Univ. of Michigan, Oct. 21, 2020, https://chemrxiv.org/engage/chemrxiv/article-details/60c75119337d6c71cfe284b0 (last visited March 3, 2026)

Exhibit No.	Description of Document
2062	Bethany Shire and Edward Anderson, <i>Conquering the Synthesis and Functionalization of Bicyclo[1.1.1]pentanes</i> , JACS Au, Vol. 3, 1539-1553 (2023), https://pubs.acs.org/doi/10.1021/jacsau.3c00014 (last visited March 3, 2026)
2063	Jonas Bostrom, et al., <i>Oxadizaoles in Medicinal Chemistry</i> , J. Med. Chem. Vol. 55, Issue 5 (Dec. 19, 2011), https://pubs.acs.org/doi/10.1021/jm2013248 (last visited March 3, 2026)
2064	Yijing Li, et al., <i>Thiadiazole-a Promising Structure in Medicinal Chemistry</i> , ChemMedChem, Vol. 8, Issue 1, 27-41 (Jan. 10, 2013), https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.201200355 (last visited March 3, 2026)
2065	Lilly Investors, <i>Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight</i> (June 24, 2023), https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine
2066	Jinzi Jason Wu and Vanessa Wang, <i>Poster: A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity</i> , Obesity Week, Ascletis.com (October 30, 2025), https://www.ascletis.com/data/upload/ueditor/20251030/Poster_ASC30_tablets_obesity_week.pdf
2067	Oana Cristina Seremet, et al., <i>Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach</i> , Medicina, 61(11), 1902 (Oct. 23, 2025), https://doi.org/10.3390/medicina61111902
2068	<i>Reserved</i>
2069	Scott Childs et al., <i>The Salt-Cocrystal Continuum: The Influence of Crystal Structure on Ionization State</i> , Molecular Pharm., Vol. 4, 323-338 (2007)

Exhibit No.	Description of Document
2070	Richard Bastin, et al., <i>Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities</i> , Am. Chem. Society, Vol. 4, 427-436 (2000)
2071	Juan Frias et al., <i>Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study</i> , The Lancet, Vol. 402 (2023)
2072	Marnix van der Kolk, et al., <i>Cyclobutanes in Small-Molecule Drug Candidates</i> , ChemMedChem, 17, e202200020 (2022)
2073	Deepak Gupta, et al., <i>Salts of Therapeutic Agents; Chemical, Physicoshemical, and Biological Considerations</i> , Molecules (2018)
2074	Brett Hopkins et al., <i>Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors</i> , ACS Med. Chem. Lett. 2021, 12, 1435–1440, https://pubs.acs.org/doi/10.1021/acsmmedchemlett.1c00265?ref=PDF
2075	Kuthuru Suresh and Ashwini Nangia, <i>Lornoxicam Salts: Crystal Structures, Conformations and Solubility</i> , Am. Chem. Society, Vol. 14, 2945-2953 (2014)
2076	Anna Astrand, et al., <i>Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes and LC-QTOF-MS</i> , Archives of Toxicology, Vol. 93, 95-106 (2019)
2077	Benjamin D. Cons, et al., <i>Electrostatic Complementarity in Structure-Based Drug Design</i> , J. of Med. Chem., Vol. 65, 7476-7488 (2022)
2078	Paul Koovits, et al., <i>Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents</i> , RCS Med. Chem., Vol. 11, 1267-1274 (2020)
2079	Original Expunged
2079	Corrected Declaration of Dr. Peter Wipf in Support of Patent Owner's Response, dated March 5, 2026
2080	Declaration of John Gargiulo in Support of Patent Owner's Response, dated March 5, 2026

Exhibit No.	Description of Document
2081	Ascleitis laboratory notebook no. GLNB007230-3
2082	Kazancioglu, M. Z., Quirion, K., Wipf, P. and Skoda, E. M., Enantioselective Synthesis and Selective Functionalization of 4-Aminotetrahydroquinolines as Novel Glp-1 Secretagogues, Chirality 2022, 34(3), 521-536
2083	Sean Wharton et al., <i>Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment</i> , New England Journal of Medicine 2025; 393:1796-806
2084	Proposed Protective Order
2085	Redline of Protective Order Compared to Default Protective Order
2086	Second Declaration of John Gargiulo, dated May 6, 2026
2087	Andrew G. Cole et al., <i>Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836</i> , Journal of Medicinal Chemistry (2024), 67, 16773-16795
2088	U.S. Patent No. 10,683,302 B2
2089	Deposition transcript of Dr. Yi Fan Ph.D. taken on June 23, 2026
2090	Patent Owner’s Demonstratives for Oral Argument on August 31, 2026

Dated: August 26, 2026

Respectfully submitted,

ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

By: /Geoffrey D. Biegler/
W. Chad Shear (Reg. No. 47,938)
Geoffrey D. Biegler (*pro hac vice*)
Isha Agarwal (*pro hac vice*)
Tae Yeon Kim (*pro hac vice*)
COOLEY LLP
ATTN: Patent Group

1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

Counsel for Patent Owner

CERTIFICATION OF SERVICE UNDER 37 C.F.R. §§ 42.6(e), 42.205(a))

I, Geoffrey D. Biegler, hereby certify that on this 26th day of August, 2026, the foregoing **PATENT OWNER'S UPDATED EXHIBIT LIST** was served electronically via email on the following:

Jin Zhu, Ph.D.
Joe G. Chen, Ph.D.
FOX ROTHSCHILD LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
jzhu@foxrothschild.com
joechen@foxrothschild.com

Luke Toft
FOX ROTHSCHILD LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
ltoft@foxrothschild.com
Dated: August 26 , 2026

ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

COOLEY LLP

By: /Geoffrey D. Biegler/
W. Chad Shear (Reg. No. 47,938)
Geoffrey D. Biegler (*pro hac vice*)
Isha Agarwal (*pro hac vice*)
Tae Yeon Kim (*pro hac vice*)
COOLEY LLP
ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

Counsel for Patent Owner